Aug
2026
COEX, Seoul, Korea
Visit us
stand K25
Zone

WEIHAI HANMI BIOCHEM CO., LTD.

Exhibitor at CPHI Korea 2026
About Us

Weihai Hanmi Biochem Co., Ltd is located in Weihai, Shandong, China, focusing on the export and import of APIs and intermidiates, food additives and cosmetic ingredients and other chemical raw materials. With an experienced and high-efficient team, we are developing rapidly and dynamically. We have good cooperation with more than hundreds pharmaceutial companies in China and all over the world, as well as we have many exclusive rights of products, which enables us to provide clients high cost-effective products and wider selectivity. What's more, we know the industry dynamics and market needs.

  • Country/Region:
    China
  • On CPHI since:
    2025
  • Employees:
    1 - 24
Company types
Distributor/Import Export
Contact info
  • 8/F C/Tower Central Green Axis, No.33, Cheng Yang Road, Huancui District, Weihai, Shandong Province, CHINA., 264200, Huancui District, China, China
Event information
CPHI Korea 2026
  • 25 Aug 2026 - 27 Aug 2026
  • COEX, Seoul, Korea
  • Visit us at stand K25

Products Featured at CPHI Korea 2026

  • Amino acid series products

    Product Amino acid series products

    L-Isoleucine, L-Leucine, L-Lysine Acetate, L-Lysine Monohydrochloride, L-Methionine, L-Phenylalanine, L-Tryptophan, L-Valine, Glycine, L-Alanine, L-Aspartic Acid, L-Glutamic acid, L-Proline, L-Serine, L-Threonine, L-Tyrosine,and other protect amino acids.
  • Gentamicin Sulfate

    Product Gentamicin Sulfate

    Gentamicin Sulfate remains a critical broad-spectrum antibiotic, primarily used in hospital settings for life-threatening infections.   Available as API or finished formulations (injectables/topicals).
  • Potassium clavulanate

    Product Potassium clavulanate

    lavulanate Potassium is a β-lactamase inhibitor used in combination with β-lactam antibiotics (e.g., amoxicillin, ticarcillin) to enhance their effectiveness against resistant bacteria.
  • Upadacitinib

    Product Upadacitinib

    JAK Inhibitor.Upadacitinib is a next-generation JAK1-selective inhibitor with proven efficacy in autoimmune diseases.  Its targeted action offers a favorable risk-benefit profile compared to older JAK inhibitors.
  • Baricitinib

    Product Baricitinib

    Potent JAK1/JAK2 inhibitor for autoimmune disease research and drug development. High purity (≥98%). CAS: 1187595-84-1.